BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9486676)

  • 1. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
    Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
    Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased frequency of skin-infiltrating FoxP3+ regulatory T cells as a diagnostic indicator of severe atopic dermatitis from cutaneous T cell lymphoma.
    Hanafusa T; Matsui S; Murota H; Tani M; Igawa K; Katayama I
    Clin Exp Immunol; 2013 Jun; 172(3):507-12. PubMed ID: 23600840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
    Rao V; Ryggen K; Aarhaug M; Dai HY; Jørstad S; Moen T
    J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1100-7. PubMed ID: 16987266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo?
    Dummer R; Posseckert G; Nestle F; Witzgall R; Burger M; Becker JC; Schäfer E; Wiede J; Sebald W; Burg G
    J Invest Dermatol; 1992 Jan; 98(1):50-4. PubMed ID: 1728640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
    Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
    Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia.
    Kamihira S; Atogami S; Sohda H; Momita S; Yamada Y; Tomonaga M
    Cancer; 1994 Jun; 73(11):2753-8. PubMed ID: 8194016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological immunomarkers in cutaneous T cell lymphoma.
    Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
    Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis.
    Miyagaki T; Sugaya M
    J Dermatol Sci; 2011 Oct; 64(1):1-6. PubMed ID: 21872448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
    Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.
    Bien E; Rapala M; Krawczyk M; Balcerska A
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):293-305. PubMed ID: 19693535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
    Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
    J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
    Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
    J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum sIL-2R and LDH levels in patients with intravascular large B-cell lymphoma and patients with advanced stage diffuse large B-cell lymphoma.
    Hirami Y; Nishimura MF; Urata T; Morimoto M; Maekawa Y; Yoshino T; Nishimura Y; Sato Y
    J Clin Exp Hematop; 2023 Mar; 63(1):25-31. PubMed ID: 36843068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.